Fonidel
- Fonidel, a Factor Xa inhibitor, is utilized for preventing deep vein thrombosis (DVT) in various surgical procedures and treating acute DVT or pulmonary embolism (PE) in conjunction with warfarin.
- Selectively targeting Factor Xa, it disrupts the blood coagulation cascade, inhibiting thrombus formation without affecting platelet function.
- Dosage varies based on the indication, with close monitoring essential for patients at heightened bleeding risk.
- Contraindications include severe renal impairment, active major bleeding, and certain hypersensitivity reactions, ensuring safe and effective management of thrombotic disorders.
- Fonidel is a critical therapeutic option in anticoagulant therapy, offering precise control and management of thrombotic conditions.
RivaXa 10
- RivaXa: Available in 2.5 mg and 10-20 mg doses.
- Prevents Atherothrombotic Events: Post-Acute Coronary Syndrome (ACS).
- Reduces Risk of Stroke and Systemic Embolism: Especially in nonvalvular atrial fibrillation.
- Highly Selective Factor Xa Inhibitor: Efficiently disrupts blood coagulation pathways.
- Manages DVT and PE: Provides effective treatment and prevention strategies.
- Careful Dosage Guidance: Ensures patient safety and well-being.